title: Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma.
abstract: OBJECTIVE
  Eukaryotic translation initiation factor 4E (eIF4E) is overexpressed in many cancer and is emerging as a potential therapeutic target. Yet data on the expression of eIF4E in endometrial cancer are lacking.
  
  
  METHODS
  Immunohistochemistry was used to evaluate the expression of eIF4E in 62 endometrial cancer surgical specimens. We subsequently evaluated whether inhibition of eIF4E by siRNA would have an impact on cell growth in endometrial cancer cell lines, using the MTT cell proliferation assay.
  
  
  RESULTS
  According to a chosen cutoff value, 36 (58.1%) of 62 patient specimens scored as eIF4E positive. The positivity of eIF4E was significantly more frequent in tumors extending outside the uterus (stage III/IV vs. stage I/II, P = 0.027). Lastly, downregulation of eIF4E by siRNA reduced the growth of HEC-1A cells significantly but had a somewhat weaker effect in Ishikawa cells (P < 0.001).
  
  
  CONCLUSIONS
  Expressions of eIF4E correlated with prognosis of endometrial adenocarcinomas. Our results suggest that eIF4E might be a promising therapeutic target in endometrial cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-Gu, Seoul, 135-710, Korea.
authors.forename: Chel Hun
authors.initials: CH
authors.lastname: Choi
authors.forename: Ji-Soo
authors.initials: JS
authors.lastname: Lee
authors.forename: Seong Rim
authors.initials: SR
authors.lastname: Kim
authors.forename: Yoo-Young
authors.initials: YY
authors.lastname: Lee
authors.forename: Chul-Jung
authors.initials: CJ
authors.lastname: Kim
authors.forename: Jeong-Won
authors.initials: JW
authors.lastname: Lee
authors.forename: Tae-Joong
authors.initials: TJ
authors.lastname: Kim
authors.forename: Je-Ho
authors.initials: JH
authors.lastname: Lee
authors.forename: Byoung-Gie
authors.initials: BG
authors.lastname: Kim
authors.forename: Duk-Soo
authors.initials: DS
authors.lastname: Bae
mesh_terms: D000328:Adult; D000368:Aged; D018269:Carcinoma, Endometrioid / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D048708:Cell Growth Processes / Q000235:genetics; D045744:Cell Line, Tumor; D018572:Disease-Free Survival; D015536:Down-Regulation; D016889:Endometrial Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D039561:Eukaryotic Initiation Factor-4E / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics; D014162:Transfection
chemical_list: D039561:Eukaryotic Initiation Factor-4E; D034741:RNA, Small Interfering
references.citation: J Cancer Res Clin Oncol. 2009 Jul;135(7):933-41
references.pmid: 19107520
references.citation: Mol Cancer Ther. 2008 Jul;7(7):1782-8
references.pmid: 18644990
references.citation: Gynecol Oncol. 2004 Mar;92(3):744-51
references.pmid: 14984936
references.citation: Cancer Treat Rev. 2007 Apr;33(2):177-90
references.pmid: 17196749
references.citation: Curr Opin Investig Drugs. 2002 Feb;3(2):295-304
references.pmid: 12020063
references.citation: Mol Cancer Ther. 2002 Sep;1(11):971-9
references.pmid: 12481419
references.citation: Br J Cancer. 1998 Jun;77(12):2120-8
references.pmid: 9649123
references.citation: Nat Rev Cancer. 2006 Sep;6(9):729-34
references.pmid: 16915295
references.citation: Am J Surg Pathol. 2002 Mar;26(3):312-9
references.pmid: 11859202
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):663-6
references.pmid: 11401917
references.citation: Oncogene. 2004 Apr 19;23(18):3189-99
references.pmid: 15094768
references.citation: Ann Surg. 2006 May;243(5):684-90; discussion 691-2
references.pmid: 16633004
references.citation: J Clin Oncol. 2006 Jan 1;24(1):36-44
references.pmid: 16330675
references.citation: Eur J Biochem. 2002 Nov;269(22):5350-9
references.pmid: 12423333
references.citation: Oncol Rep. 2008 Dec;20(6):1409-17
references.pmid: 19020722
references.citation: Cancer. 1997 Jun 15;79(12):2385-90
references.pmid: 9191527
references.citation: Crit Rev Oncol Hematol. 2006 Jun;58(3):242-56
references.pmid: 16436330
references.citation: Ann Surg. 1998 May;227(5):756-6l; discussion 761-3
references.pmid: 9605667
references.citation: Ann Surg. 2002 May;235(5):732-8; discussion 738-9
references.pmid: 11981220
references.citation: Gynecol Oncol. 1991 Jan;40(1):55-65
references.pmid: 1989916
references.citation: Curr Opin Obstet Gynecol. 2002 Feb;14(1):59-65
references.pmid: 11801878
references.citation: Clin Exp Metastasis. 2003;20(3):265-73
references.pmid: 12741684
references.citation: J Clin Invest. 2007 Sep;117(9):2638-48
references.pmid: 17786246